Psychiatrists effect on positive symptom severity and daily functioning during pharmacotherapy for first-episode psychosis patients.
Antipsychotic agents
Psychiatrists
Psychotic disorders
Severity of illness
Treatment outcome
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
received:
19
02
2024
accepted:
10
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
2
10
2024
Statut:
epublish
Résumé
Clinical outcomes after a first-episode of psychosis (FEP) are heterogeneous. Many patient-related factors such as gender and comorbidity have been studied to predict symptomatic outcomes. However, psychiatrist-related factors such as prescription behaviour and gender have received little attention. We assessed the relationship between patients' psychiatrists, psychosis severity and daily functioning in 201 patients remitted from an FEP for a duration of one year, treated by 18 different psychiatrists. We controlled for baseline severity, dose and type of antipsychotic medication, frequency of visits, and patients' education. Symptom severity, daily functioning, and antipsychotic drug use were assessed at baseline and at 3, 6, and, 12 months follow-up. We found that psychiatrists accounted for 9.1% of the explained variance in patients' symptom severity and 10.1% of the explained variance in daily functioning.These effects persisted even when controlling for factors such as baseline severity and the prescribed dose. The effect of prescribed dose on symptom severity and daily functioning differed between psychiatrists. Treatment centre, session frequency, and medication nonadherence were not related to symptom severity. Our results emphasize the importance of individual psychiatrist factors in symptomatic outcomes after an FEP. Further identification of psychiatrist-related factors such as the quality of therapeutic alliances and shared decision-making, may optimize psychiatrists' training with the goal of improving patient outcomes.
Identifiants
pubmed: 39358381
doi: 10.1038/s41598-024-72678-4
pii: 10.1038/s41598-024-72678-4
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22871Subventions
Organisme : ZonMw
ID : 348041003
Pays : Netherlands
Investigateurs
Joran Lokkerbol
(J)
Iris E C Sommer
(IEC)
Iris Sommer
(I)
Lieuwe de Haan
(L)
Wim Veling
(W)
Jim van Os
(J)
Filip Smit
(F)
Marieke Begemann
(M)
Sanne Schuite-Koops
(S)
Machteld Marcelis
(M)
Martijn Kikkert
(M)
Nico van Beveren
(N)
Nynke Boonstra
(N)
Bram-Sieben Rosema
(BS)
Sinan Gülöksüz
(S)
P Roberto Bakker
(PR)
Joran Lokkerbol
(J)
Bodyl Brand
(B)
Shiral Gangadin
(S)
Erna Van't Hag
(EV)
Priscilla Oomen
(P)
Alban Voppel
(A)
Iris Hamers
(I)
Matej Djordjevic
(M)
Toon Scheurink
(T)
Therese van Amelsvoort
(T)
Maarten Bak
(M)
Steven Berendsen
(S)
Truus van den Brink
(T)
Gunnar Faber
(G)
Koen Grootens
(K)
Martijn de Jonge
(M)
Henderikus Knegtering
(H)
Jörg Kurkamp
(J)
Gerdina Hendrika Maria Pijnenborg
(GHM)
Anton B P Staring
(ABP)
Natalie Veen
(N)
Selene Veerman
(S)
Sybren Wiersma
(S)
Albert Batalla Cases
(AB)
Ruben Curfs
(R)
Jan-Jaap Hage
(JJ)
Ellen Graveland
(E)
Joelle Hoornaar
(J)
Inge van der Heijden
(I)
Informations de copyright
© 2024. The Author(s).
Références
Simonsen, C. et al. Early clinical recovery in first-episode psychosis: Symptomatic remission and its correlates at 1-year follow-up. Psychiatry Res.254, 118–125 (2017).
doi: 10.1016/j.psychres.2017.04.050
pubmed: 28460281
Priebe, S., Conneely, M., McCabe, R. & Bird, V. What can clinicians do to improve outcomes across psychiatric treatments: A conceptual review of non-specific components. Epidemiol. Psychiatr. Sci. https://doi.org/10.1017/S2045796019000428 (2019).
doi: 10.1017/S2045796019000428
pubmed: 31412975
pmcid: 8061300
Walwyn, R. & Roberts, C. Therapist variation within randomised trials of psychotherapy: Implications for precision, internal and external validity. Stat. Methods Med. Res.19, 291–315 (2010).
doi: 10.1177/0962280209105017
pubmed: 19608603
Berry, K., Gregg, L., Lobban, F. & Barrowclough, C. Therapeutic alliance in psychological therapy for people with recent onset psychosis who use cannabis. Compr. Psychiatry67, 73–80 (2016).
doi: 10.1016/j.comppsych.2016.02.014
pubmed: 27095338
McCabe, R. et al. Training to enhance psychiatrist communication with patients with psychosis (TEMPO): Cluster randomised controlled trial. Br. J. Psychiatry209, 517–524 (2016).
doi: 10.1192/bjp.bp.115.179499
pubmed: 27445354
Da Costa, H., Martin, B. & Franck, N. Determinants of therapeutic alliance with people with psychotic disorders: A systematic literature review. J. Nerv. Mental Disease208, 329–339 (2020).
doi: 10.1097/NMD.0000000000001125
Day, J. C. et al. Attitudes toward antipsychotic medication: The impact of clinical variables and relationships with health professionals. Arch. Gen. Psychiatry62, 717–724 (2005).
doi: 10.1001/archpsyc.62.7.717
pubmed: 15997012
Browne, J., Nagendra, A., Kurtz, M., Berry, K. & Penn, D. L. The relationship between the therapeutic alliance and client variables in individual treatment for schizophrenia spectrum disorders and early psychosis: Narrative review. Clin. Psychol. Rev.71, 51–62 (2019).
doi: 10.1016/j.cpr.2019.05.002
pubmed: 31146249
de Jong, S. et al. Longitudinal assessments of therapeutic alliance predict work performance in vocational rehabilitation for persons with schizophrenia. Psychol. Psychother. Theory Res. Pract.94, 915–928 (2021).
doi: 10.1111/papt.12346
Priebe, S., Richardson, M., Cooney, M., Adedeji, O. & McCabe, R. Does the therapeutic relationship predict outcomes of psychiatric treatment in patients with psychosis? A systematic review. Psychother. Psychosom.80, 70–77 (2011).
doi: 10.1159/000320976
pubmed: 21196804
Shattock, L., Berry, K., Degnan, A. & Edge, D. Therapeutic alliance in psychological therapy for people with schizophrenia and related psychoses: A systematic review. Clin. Psychol. Psychother.25, e60 (2018).
doi: 10.1002/cpp.2135
pubmed: 28961352
Saxon, D., Firth, N. & Barkham, M. The relationship between therapist effects and therapy delivery factors: Therapy modality, dosage, and non-completion. Adm. Policy Mental Health Mental Health Serv. Res.44, 705–715 (2017).
doi: 10.1007/s10488-016-0750-5
Barkham, M., Lutz, W., Lambert, M. J. & Saxon, D. Therapist effects, effective therapists, and the law of variability. In How and Why are Some Therapists Better Than Others?: Understanding Therapist Effects (eds Hill, C. E. & Castonguay, L. G.) 13–36 (American Psychological Association, 2017).
doi: 10.1037/0000034-002
Wampold, B. E. & Brown, G. S. Estimating variability in outcomes attributable to therapists: A naturalistic study of outcomes in managed care. J. Consult. Clin. Psychol.73, 914–923 (2005).
doi: 10.1037/0022-006X.73.5.914
pubmed: 16287391
Zisman-Ilani, Y., Roth, R. M. & Mistler, L. A. Time to support extensive implementation of shared decision making in psychiatry. JAMA Psychiatry78, 1183–1184 (2021).
doi: 10.1001/jamapsychiatry.2021.2247
pubmed: 34406346
Wienke Totura, C. M., Fields, S. A. & Karver, M. S. The role of the therapeutic relationship in psychopharmacological treatment outcomes: A meta-analytic review. Psychiatr. Serv.69, 41–47 (2018).
doi: 10.1176/appi.ps.201700114
McKay, K. M., Imel, Z. E. & Wampold, B. E. Psychiatrist effects in the psychopharmacological treatment of depression. J. Affect. Disord.92, 287–290 (2006).
doi: 10.1016/j.jad.2006.01.020
pubmed: 16503356
Strunk, D. R. et al. Can pharmacotherapists be too supportive? A process study of active medication and placebo in the treatment of depression. Psychol. Med.40, 1379–1387 (2010).
doi: 10.1017/S0033291709991553
pubmed: 19891806
Harris, B. A. & Panozzo, G. Therapeutic alliance, relationship building, and communication strategies-for the schizophrenia population: An integrative review. Arch. Psychiatr. Nurs.33, 104–111 (2019).
doi: 10.1016/j.apnu.2018.08.003
pubmed: 30663612
Kodaka, F. et al. Relationships between adherence to guideline recommendations for pharmacological therapy among clinicians and psychotic symptoms in patients with schizophrenia. Int. J. Neuropsychopharmacol.26, 557–565 (2023).
doi: 10.1093/ijnp/pyad037
pubmed: 37381793
pmcid: 10464927
Lombarts, K. M. J. & Verghese, A. Medicine is not gender-neutral—She is male. N. Engl. J. Med.24, 2368–2375 (2022).
Begemann, M. J. H. et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials21, 1–19 (2020).
doi: 10.1186/s13063-019-3822-5
Andreassen, N., Flaum, M. & Arndt, S. The Comprehensive Assessment of Symptoms and History (CASH) an instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry49, 615–623 (1992).
doi: 10.1001/archpsyc.1992.01820080023004
Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull.13, 261–276 (1987).
doi: 10.1093/schbul/13.2.261
pubmed: 3616518
Chopra, P., Herrman, H. & Kennedy, G. Comparison of disability and quality of life measures in patients with long-term psychotic disorders and patients with multiple sclerosis: An application of the WHO Disability Assessment Schedule II and WHO Quality of Life-BREF. Int. J. Rehabilit. Res.31, 141–149 (2008).
doi: 10.1097/MRR.0b013e32830150e6
Leucht, S. et al. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am. J. Psychiatry177, 342–353 (2020).
doi: 10.1176/appi.ajp.2019.19010034
pubmed: 31838873
Bouwmans, C. et al. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). BMC Health Serv. Res.13, 217 (2013).
doi: 10.1186/1472-6963-13-217
pubmed: 23768141
pmcid: 3694473
Bates, D., Maechler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw.67, 1–48 (2015).
doi: 10.18637/jss.v067.i01
Nakagawa, S. & Schielzeth, H. A general and simple method for obtaining R2 from generalized linear mixed-effects models. Methods Ecol. Evol.4, 133–142 (2013).
doi: 10.1111/j.2041-210x.2012.00261.x
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. www.R-project.org Preprint at (2020).
Wright, M. N. & Ziegler, A. ranger: A fast implementation of random forests for high dimensional data in C++ and R. J. Stat. Softw. https://doi.org/10.18637/jss.v077.i01 (2016).
doi: 10.18637/jss.v077.i01
Chang, J. G., Roh, D. & Kim, C. Association between therapeutic alliance and adherence in outpatient schizophrenia patients. Clin. Psychopharmacol. Neurosci.17, 273–278 (2019).
doi: 10.9758/cpn.2019.17.2.273
pubmed: 30905127
pmcid: 6478080
Tang, C. J., Chan, S. W., Zhou, W. T. & Liaw, S. Y. Collaboration between hospital physicians and nurses: An integrated literature review. Int. Nurs. Rev.60, 291–302. https://doi.org/10.1111/inr.12034 (2013).
doi: 10.1111/inr.12034
pubmed: 23961790